[go: up one dir, main page]

WO2013045668A3 - Immunotherapy composition and regimen for treating hepatitis c virus infection - Google Patents

Immunotherapy composition and regimen for treating hepatitis c virus infection Download PDF

Info

Publication number
WO2013045668A3
WO2013045668A3 PCT/EP2012/069272 EP2012069272W WO2013045668A3 WO 2013045668 A3 WO2013045668 A3 WO 2013045668A3 EP 2012069272 W EP2012069272 W EP 2012069272W WO 2013045668 A3 WO2013045668 A3 WO 2013045668A3
Authority
WO
WIPO (PCT)
Prior art keywords
regimen
immunotherapy composition
virus infection
treating hepatitis
immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/069272
Other languages
French (fr)
Other versions
WO2013045668A2 (en
Inventor
Géraldine HONNET
Bernard BURTIN
Delphine AGATHON
Jean-Marc Limacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of WO2013045668A2 publication Critical patent/WO2013045668A2/en
Publication of WO2013045668A3 publication Critical patent/WO2013045668A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the field of immunotherapy and more specifically to a composition comprising non-structural (NS) HCV antigens or expression vector(s) thereof for use for treating ahepatitis C virus (HCV) infection. The present invention as also relates to a therapeutic regimen comprising the step of administrating to a subject such an immunotherapy composition as well as a kit of parts comprising a plurality of containers and instructions for carrying out said therapeutic regimen. The immunotherapy composition, kit and therapeutic regimen can be used in combination with antiviral therapy (e.g. interferon therapy and/or ribavirin).
PCT/EP2012/069272 2011-09-29 2012-09-28 Immunotherapy composition and regimen for treating hepatitis c virus infection Ceased WO2013045668A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP11306248.3 2011-09-29
EP11306248 2011-09-29
EP11306433 2011-11-04
EP11306433.1 2011-11-04
EP11306441.4 2011-11-07
EP11306441 2011-11-07

Publications (2)

Publication Number Publication Date
WO2013045668A2 WO2013045668A2 (en) 2013-04-04
WO2013045668A3 true WO2013045668A3 (en) 2013-06-06

Family

ID=46924495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/069272 Ceased WO2013045668A2 (en) 2011-09-29 2012-09-28 Immunotherapy composition and regimen for treating hepatitis c virus infection

Country Status (2)

Country Link
TW (1) TW201321016A (en)
WO (1) WO2013045668A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136740A1 (en) * 2000-08-17 2002-09-26 Matti Sallberg Vaccines containing ribavirin and methods of use thereof
US20070269460A1 (en) * 2003-06-05 2007-11-22 Transgene S.A. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
WO2010117936A1 (en) * 2009-04-06 2010-10-14 Schering Corporation Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2650838A1 (en) 1989-08-09 1991-02-15 Transgene Sa FACTOR IX EXPRESSION VECTORS IN A SUPERIOR EUKARYOTE CELL, PROCESS FOR THE PREPARATION OF FACTOR IX BY TRANSGENIC ANIMALS, AND FACTOR IX OBTAINED
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
NZ335947A (en) 1996-11-20 2000-12-22 Introgen Therapeutics Inc A method for the production and purification of adenoviral vectors
ES2283032T3 (en) 1996-12-13 2007-10-16 Schering Corporation METHODS TO PURIFY VIRUSES.
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
JP3864610B2 (en) 1998-05-21 2007-01-10 旭硝子株式会社 Water-dispersed water / oil repellent composition and method for producing the same
WO2000040702A1 (en) 1998-12-31 2000-07-13 Aventis Pharma S.A. Method for separating viral particles
EP1155120B1 (en) 1999-02-22 2006-07-05 Transgene S.A. Method for obtaining a purified viral preparation
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2003000283A1 (en) 2001-06-22 2003-01-03 The Wistar Institute Of Anatomy And Biology Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
NZ564586A (en) 2001-11-21 2009-09-25 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
FR2836924B1 (en) 2002-03-08 2005-01-14 Vivalis AVIAN CELL LINES USEFUL FOR THE PRODUCTION OF INTEREST SUBSTANCES
FR2855758B1 (en) 2003-06-05 2005-07-22 Biomerieux Sa COMPOSITION COMPRISING NS3 / NS4 POLYPROTEIN AND HCV NS5B POLYPEPTIDE, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR USE IN THERAPEUTICS
PL2163260T3 (en) 2004-01-23 2017-12-29 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
RU2415867C2 (en) 2006-01-05 2011-04-10 Трансген С.А. Avian telomerase reverse transcriptase
JP2009541236A (en) 2006-06-20 2009-11-26 トランジェーヌ、ソシエテ、アノニム Recombinant virus vaccine
DK2029756T3 (en) 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
TWI614342B (en) 2007-07-03 2018-02-11 存斯精菱公司 Immortalized avian cell lines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
SG186022A1 (en) 2007-11-28 2012-12-28 Univ Pennsylvania Simian subfamily b adenovirus sadv-28,27,-29,-32,-33, and -35 and uses thereof
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
WO2009073104A2 (en) 2007-11-28 2009-06-11 The Trustees Of The University Of Pennsylvania Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38
US8470310B2 (en) 2008-03-04 2013-06-25 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof
JP2012503011A (en) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド Immunotherapy of chronic hepatitis C virus infection
CA2749325C (en) 2009-02-02 2021-03-30 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CN103547285A (en) 2009-05-12 2014-01-29 特兰斯吉恩股份有限公司 Immortalized avian cell lines and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136740A1 (en) * 2000-08-17 2002-09-26 Matti Sallberg Vaccines containing ribavirin and methods of use thereof
US20070269460A1 (en) * 2003-06-05 2007-11-22 Transgene S.A. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
WO2010117936A1 (en) * 2009-04-06 2010-10-14 Schering Corporation Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANCOIS HABERSETZER ET AL: "A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 141, no. 3, 3 June 2011 (2011-06-03), pages 890 - 899.e4, XP028273467, ISSN: 0016-5085, [retrieved on 20110613], DOI: 10.1053/J.GASTRO.2011.06.009 *

Also Published As

Publication number Publication date
WO2013045668A2 (en) 2013-04-04
TW201321016A (en) 2013-06-01

Similar Documents

Publication Publication Date Title
MX354958B (en) Methods for treating hcv.
AR084237A1 (en) METHODS TO TREAT HEPATITIS C (HCV) VIRUSES, COMPOSITION
MD20140058A2 (en) Compositions and methods for treating hepatitis C virus
MX337936B (en) Hepatitis c virus inhibitors.
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
MX2011007195A (en) Cyclosporine derivative for use in the treatment of hcv and hiv infection.
BR112013028679A2 (en) hepatitis c virus inhibitors
ZA201403852B (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
IN2012MN02896A (en)
WO2012006500A3 (en) Monoclonal antibodies against hepatitis c virus core protein
PL2909205T3 (en) 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
BR112014010295A2 (en) methods and compositions for the treatment of hepatitis c virus
WO2013036622A3 (en) Antiviral peptides effective against hepatitis c virus
IL225861A (en) Derivatives of indazole-3-carboxamide and use thereof in the manufacture of medicaments for the treatment of hepatitis c virus (hcv) infection
PH12014500283A1 (en) Hcv immunotherapy
IN2015DN03925A (en)
WO2013045668A3 (en) Immunotherapy composition and regimen for treating hepatitis c virus infection
NZ602552A (en) Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
WO2010081095A3 (en) Methods and compositions for inhibiting hepatitis c virus replication
WO2012097123A3 (en) New uses of cyclophilin inhibitors
MX2018000213A (en) Methods for treating hcv.
Evans Peginterferon-α/ribavirin/telaprevir
UA114097C2 (en) COMPOSITION (OPTIONS) AND METHOD (OPTIONS) OF TREATMENT OF VIRAL HEPATITIS C

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12762658

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12762658

Country of ref document: EP

Kind code of ref document: A2